Ukko
Tel Aviv, Israel· Est.
AI‑powered protein design company developing hypoallergenic immunotherapies for food allergies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered protein design company developing hypoallergenic immunotherapies for food allergies.
AllergyImmunology
Technology Platform
AI‑driven computational protein design platform that engineers hypoallergenic variants of food allergens to induce immune tolerance without triggering IgE‑mediated responses.
Opportunities
Rapidly growing food‑allergy market and the ability to generate multiple hypoallergenic candidates quickly via AI give Ukko a strong pipeline expansion potential.
Risk Factors
Regulatory uncertainty for engineered protein therapeutics and the need to demonstrate safety and efficacy in early human trials pose significant execution risks.
Competitive Landscape
Ukko competes with companies like Aimmune, DBV Technologies, and Pas Therapeutics, but differentiates itself through its AI‑based protein design platform that can accelerate candidate discovery and reduce development costs.